Viking Therapeutics stock jumps nearly 30% after drugmaker moves weight loss injection to late-stage trial
Publishing timestamp: 2024-07-25 16:03:38
Summary
Viking Therapeutics announced plans to advance its weight loss injection into late-stage trial earlier than expected, leading to a jump in its shares. The company is aiming to compete in the highly popular market for GLP-1s, which analysts predict could grow into a $150 billion market by the end of the decade.
Sentiment: POSITIVE
Tickers: LLY, VKTX, NOVO.B-DK,
Keywords: business, breaking news, breaking news: business, viking therapeutics inc, novo nordisk a/s, business news, biotechnology, biotech and pharmaceuticals, health care industry, eli lilly and co, pharmaceuticals,